Autopsy report · NCT05145569

Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer

“Per PI and agent sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Haider Mahdi

Sponsor type

University, hospital or other

Conditions

Ovarian Cancer

Interventions

Carboplatin AUC 5 and paclitaxel; HCW9218

Participants

0

Trials that died the same way

• Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve
  “Sponsor \& PI decision” (74% match in meaning)
• Value of 3D Modeling in Spine Surgery
  “Sponsor and PI decision” (74% match in meaning)
• A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®
  “Per Sponsor” (72% match in meaning)
• An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
  “Sponsor resource allocation” (62% match in meaning)
• Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma
  “Industry sponsor decision” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.